Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Dillon

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
Frontiers in Oncology|September 9, 2020
Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in LondonBeth Russell, Charlotte Moss, Sophie Papa, et al.
Leukemia|April 13, 2026
Elevated levels of TNF and its targets characterize better-risk older acute myeloid leukemia patientsYaseswini Neelamraju, Franck Rapaport, Jorge A Gandara, et al.
Blood|December 12, 2022
Overlapping features of therapy-related and de novo NPM1-mutated AMLJad Othman, Manja Meggendorfer, Enrico Tiacci, et al.
Blood Advances|September 12, 2024
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapyJad Othman, Angela Hwang, Maximillian Brodermann, et al.
Blood Advances|December 1, 2023
Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AMLCarlos Jimenez-Chillon, Jad Othman, David Taussig, et al.
Blood|August 30, 2023
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapyJad Othman, Ing S Tiong, Jenny O'Nions, et al.
Blood|July 12, 2019
Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemiaAntonio R Lucena-Araujo, Juan L Coelho-Silva, Diego A Pereira-Martins, et al.
Blood Cancer Discovery|July 3, 2025
Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease StatesCurtis A Lachowiez, Georgios Asimomitis, Elsa Bernard, et al.
Blood|January 15, 2020
Molecular MRD status and outcome after transplantation in NPM1-mutated AMLRichard Dillon, Robert Hills, Sylvie Freeman, et al.
Leukemia|August 9, 2023
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AMLJad Othman, Nicola Potter, Katya Mokretar, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
Frontiers in Oncology|September 9, 2020
Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in LondonBeth Russell, Charlotte Moss, Sophie Papa, et al.
Leukemia|April 13, 2026
Elevated levels of TNF and its targets characterize better-risk older acute myeloid leukemia patientsYaseswini Neelamraju, Franck Rapaport, Jorge A Gandara, et al.
Blood|December 12, 2022
Overlapping features of therapy-related and de novo NPM1-mutated AMLJad Othman, Manja Meggendorfer, Enrico Tiacci, et al.
Blood Advances|September 12, 2024
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapyJad Othman, Angela Hwang, Maximillian Brodermann, et al.
Blood Advances|December 1, 2023
Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AMLCarlos Jimenez-Chillon, Jad Othman, David Taussig, et al.
Blood|August 30, 2023
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapyJad Othman, Ing S Tiong, Jenny O'Nions, et al.
Blood|July 12, 2019
Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemiaAntonio R Lucena-Araujo, Juan L Coelho-Silva, Diego A Pereira-Martins, et al.
Blood Cancer Discovery|July 3, 2025
Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease StatesCurtis A Lachowiez, Georgios Asimomitis, Elsa Bernard, et al.
Blood|January 15, 2020
Molecular MRD status and outcome after transplantation in NPM1-mutated AMLRichard Dillon, Robert Hills, Sylvie Freeman, et al.
Leukemia|August 9, 2023
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AMLJad Othman, Nicola Potter, Katya Mokretar, et al.
Pageof 11